| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 4 Aug 2025 | 23 Jul 2025 |
| Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2025 inter alia to consider and approve Intimation of Board Meeting for consideration of unaudited Financial Results for the quarter ended June 30 2025 and Dividend. The Board of Directors of the Company at its meeting held today, August 4, 2025, has, inter alia, considered and approved: - 1. the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. 2. the payment of interim dividend of 400% i.e. Rs.4.00 (Rupee Four only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has fixed August 8, 2025, as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before August 21, 2025. (As Per BSE Announcement Dated on:04.08.2025) | ||
| Board Meeting | 26 May 2025 | 16 May 2025 |
| Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve Intimation of Board meeting to be held on May 26 2025 to consider Audited Financial Results for the fourth quarter and financial year ended March 31 2025. Intimation of appointment of Secretarial Auditors (As Per BSE Announcement dated on 26.05.2025) | ||
| Board Meeting | 6 Feb 2025 | 17 Jan 2025 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve Intimation of Board Meeting to be held on February 6 2025 to consider and approve inter alia the standalone and consolidated Unaudited financials results of the company for the third quarter and Nine months period ended December 312024 Intimation of outcome of the Board meeting held on February 6, 2025 (As Per Bse Announcement Dated on 06.02.2025) | ||
| Board Meeting | 9 Nov 2024 | 1 Nov 2024 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve Intimation of Board meeting to be held on Saturday November 9 2024 to consider and approve inter alia the Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2024. In accordance with the provisions of Regulations 30 and all other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today, November 9, 2024, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2024, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. (As Per BSE Announcement Dated on 09.11.2024) Submitting the corrigendum to the unaudited financial results for the quarter and half year ended 30.09.2024. (As Per BSE Announcement Dated on 10.11.2024) In accordance with the provisions of Regulations 30 and all other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today, November 9, 2024, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2024, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. (As Per BSE Announcement Dated on: 09/11/2024) | ||
The company announced an operating EBITDA of ₹1,603 Crore, registering a marginal decline of 1% year-on-year.
Here are some of the stocks that may see significant price movement today: LTIMindtree, Paytm, Aurobindo Pharma, etc.
Lannett is a legacy pharmaceutical firm founded in 1942. It is headquartered in Trevose, Pennsylvania, brings with it a deep expertise in manufacturing complex generics.
Here are some of the stocks that may see significant price movement today: FSN E-Commerce, Voltas Limited, Aurobindo Pharma, etc.
Dyrupeg is used primarily to reduce the risk of infection in cancer patients undergoing chemotherapy.
Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.
Annual income at the company also grew by a big margin of ₹31,724 crore in FY25 from ₹29,002 crore in FY24, up 9.4% on yearly basis
Here are some of the stocks that may see significant price movement today: Gensol Engineering, Oberoi Realty, TVS Motor Company, etc.
Aurobindo Pharma is going to launch Dasatinib in Q1 FY26, which will be in line with its plans to enhance its oncology portfolio in the US generics market.
Following the audit, the US FDA issued a Form 483 with 11 observations at closure, which Aurobindo Pharma described as small procedural observations.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
